Abstract
The objective: to evaluate the effect of a postbiotic based on Lactobacillus (L.) delbrueckii subsp. bulgaricus lysate on indicators of endotoxemia, cognitive functions, subjective fatigue, and quality of life in patients with metabolic dysfunction-associated steatotic liver disease (MASLD).Materials and methods. An open-label, pilot, single-center, prospective study with pre- and post-intervention assessment was conducted. The final analysis included 31 patients with a verified diagnosis of MASLD. All participants received a 30-day course of a postbiotic based on L. delbrueckii subsp. bulgaricus lysate. Changes in blood serum lipopolysaccharide-binding protein (LBP) concentration and fatigue severity assessed via the Fatigue Impact Scale (FIS) served as primary endpoints. Secondary endpoints included the dynamics of cognitive functions evaluated using the Animal Naming Test (ANT), and quality of life measures assessed with the EuroQol 5-Dimension 5-Level Questionnaire and the Visual Analog Scale (VAS).Results. Following the 30-day of postbiotic use a significant decrease in mean blood serum LBP level was observed (p < 0.001) with a large effect size (d = 1.63), which may indicate a reduction in endotoxemia. Cognitive functions significantly improved based on the rapid ANT results (p < 0.001; d = 0.95). Concurrently, a statistically significant reduction in the total FIS score was found (p = 0.0015; d = 0.63), accompanied by a parallel improvement in the subjective self-assessment of general health status according to the VAS (p = 0.003; d = 0.59). Structural Equation Modeling demonstrated that the association between reductions in LBP level and decreased fatigue in patients with MASLD may be partially mediated by improvements in cognitive function, whereas the direct effect remained statistically non-significant.Conclusions. In patients with MASLD, administration of a postbiotic based on a lysate of L. delbrueckii subsp. bulgaricus was associated with reductions in LBP level, improvement in cognitive function, and decreased subjective fatigue. Given the open-label uncontrolled study design, small sample size, and short follow-up period, these findings should be considered preliminary. The results obtained support further investigation into targeted modulation of the “gut-liver” axis in randomised controlled trials.